Möchten Sie immer auf dem neuesten Stand bleiben?

Diamyd appoints Peter Zerhouni as President The Board of Diamyd Medical has appointed Peter Zerhouni, Acting President of Diamyd Medical AB, as President of the Company. Peter Zerhouni has been...

Diamyd utser Peter Zerhouni till VD Diamyd Medicals styrelse har utsett Peter Zerhouni, tillförordnad VD i Diamyd Medical AB, till VD i bolaget. Peter Zerhouni har varit involverad i bolagets...

Quarterly Report III 10/11 Quarterly report, Stockholm, July 1, 2011 September 1, 2010 - May 31, 2011 Third quarter report for Diamyd Medical AB (publ.), fiscal year 2010/2011 (www.omxgroup.com...

Delårsrapport III 10/11 Delårsrapport Stockholm 1 juli 2011 1 september 2010 - 31 maj 2011 Delårsrapport 3 Diamyd Medical AB (publ.), räkenskapsåret 2010/2011 (www.omxgroup.com ticker: DIAM B;...

Diamyd increases shareholding in Protein Sciences Corporation Diamyd Medical AB announced today that the Company's convertible promissory note in the US vaccine company Protein Sciences...

Diamyd ökar aktieinnehavet i Protein Sciences Corporation Diamyd Medical meddelar idag att bolagets konvertibla skuldebrev i det amerikanska vaccinbolaget Protein Sciences Corporation, har...

Diamyd presents detailed results of European Phase III study Diamyd Medical AB reports detailed results from the Company's European Phase III study of the antigen-based diabetes therapy Diamyd®,...

Diamyd presenterar detaljerade resultat från europeisk fas III-studie Diamyd Medical AB meddelar de detaljerade resultaten från bolagets europeiska fas III-studie med den antigenbaserade...

TrialNet presents results from a study with Diamyd® Diamyd Medical AB reports that the results of a study with the Company's antigen-based diabetes therapy Diamyd®, conducted by the...

TrialNet presenterar resultat från studie med Diamyd® Diamyd Medical AB meddelar att resultaten av en studie med bolagets antigenbaserade diabetesterapi Diamyd® som genomförs av forskningskonsortiet...